By Eric Sagonowsky
As Pfizer’s COVID-19 vaccine comes into the home stretch on the R&D side, the drugmaker is scaling up an ambitious supply chain and distribution system aimed at delivering hundreds of millions of doses around the world as quickly as possible.
read more
By Robert King
COVID-19 cases are on the rise practically everywhere, as cases are increasing across 75% of the country, according to the CDC.
read more
By Amirah Al Idrus
A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday. Despite the death, the study will carry on as normal, Reuters said.
read more
By Nick Paul Taylor
AstraZeneca could resume the U.S. clinical trial of its COVID-19 vaccine this week, according to a Reuters report. The trial has been paused since early September while the FDA reviews the safety of the vaccine in light of a reported case of a rare spinal inflammatory disorder in the wider program.
read more
By Angus Liu
Roche’s arthritis therapy Actemra was one of the earliest-identified COVID-19 treatment prospect. But three new clinical studies have shown mixed results with seemingly contradictory results, leaving one infectious disease expert ruling that existing data do not support routine use of the drug in COVID-19.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
A patient given a placebo in AstraZeneca's phase 3 vaccine trial died, Reuters reports. California will run independent reviews of FDA-approved vaccines. Pfizer could snare $3.5 billion in 2021 vaccine sales, analysts predict. Aridis aims to test its inhaled antibody in humans next year. And Stanford Medicine launched a massive testing program in San Francisco.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Heather Landi
When the COVID-19 pandemic hit earlier this year, health system executives had to shift their priorities to fast-track innovations such as virtual care services and artificial intelligence tools. Here's how the COVID-19 pandemic changed healthcare executives' focus on technology and what to expect in 2021.
read more
By Ben Adams
IQVIA is still steering around COVID-19 roadblocks with its R&D business still posting a loss, but other segments are recovering as it ups its full-year guidance.
read more
By Tina Reed
As Tenet Healthcare reported its third-quarter earnings on Tuesday, CEO Ronald A. Rittenmeyer said it shaped up to be "in many ways more challenging than the second, with COVID positive inpatient census surging by approximately 64% in our markets in late July and August."
read more
By Conor Hale
As a top producer of diagnostic test kits, laboratory hardware and supplies, Thermo Fisher Scientific has been a major player in the global response to the COVID-19 pandemic almost from the start—and now, the company has shown exactly how major.
read more
By Kyle Blankenship
Eli Lilly's chances at an emergency use authorization for its COVID-19 antibody took a big hit after a major trial was stopped for safety issues and the FDA flagged a site producing the therapy for data handling concerns. Now, the FDA is back for more, and it could spell even bigger problems.
read more
By Conor Hale
Stanford University and its school of medicine have launched plans to survey the population of greater San Francisco for COVID-19, in an effort to build an early warning system for future outbreaks.
read more
